Combination of GLP-1 Receptor Activation and Glucagon Blockage Promotes Pancreatic β-Cell Regeneration In Situ in Type 1 Diabetic Mice

Figure 1

Body weight, blood glucose, plasma insulin, and glucagon levels in T1D and control mice treated with liraglutide, GCGR mAb, or both for four weeks. Eight-week-old male C57BL/6J mice were injected intraperitoneally with 150 mg/kg streptozotocin (STZ) to establish a T1D model. Diabetic mice were treated with liraglutide (Lira, 200 μg/kg), GCGR mAb (5 mg/kg), or liraglutide combined with GCGR mAb. The littermate C57BL/6J mice were used as normal control: (a) body weight; (b) random blood glucose; (c) fasting blood glucose; (d) plasma glucagon; (e) plasma insulin. Data are presented as the ( mice per group). Statistical analysis was conducted by ANOVA. vs. control group; ^# vs. STZ group; ^△ vs. GCGR mAb group.

(a)

(b)

(c)

(d)

(e)